MoherDHopewellSSchulzKF. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ2010; 340: c869.
2.
GuyattGHOxmanADVistG. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). J Clin Epidemiol2011; 64: 407–415.
3.
MegaJLBraunwaldEMohanaveluS. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet2009; 374: 29–38.
AklEABrielMYouJJ. Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. BMJ2012; 344: e2809.
6.
AsselbergsFWDiercksGFHillegeHL. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation2004; 110: 2809–2816.
7.
WalshMSrinathanSKMcAuleyDF. The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index. J Clin Epidemiol2014; 67: 622–628.
